Tafamidis reduces the burden of atrial fibrillation in patients with wild-type transthyretin amyloid cardiomyopathy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Amyloid and acute heart failure therapy advances Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by